INVO Bioscience, Inc. INVO
Set alert
0.83 +0.83 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 3.25M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -4.17
- Beta
- 1.44
- Short ratio
- 0.04
- Inst. own
- 3.10%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2024
- 50-d avg
- 0.773565
- 200-d avg
- 0.901579
- 1y target
- 0.00
2Y chart
Events in this range
- Jul 28, 2023Split: 1 for 20
- Aug 14, 2023Earnings: —; estimate 0; surprise —%
- Nov 13, 2023Earnings: —; estimate 0; surprise —%
- May 15, 2024Earnings: —; estimate 0; surprise —%
- Aug 14, 2024Earnings: —; estimate 0; surprise —%
Signals (76)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 17, 2024 | 2 years ago |
| SMA: Bullish | Oct 14, 2024 | 2 years ago |
| SMA: Bullish | Oct 14, 2024 | 2 years ago |
| RSI: Overbought | Oct 14, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 24, 2024 | 2 years ago |
| SMA: Bearish | Aug 16, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 15, 2024 | 2 years ago |
| SMA: Bullish | Jul 29, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 26, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 25, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 15, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 1, 2024 | 2 years ago |
| SMA: Bearish | Jun 18, 2024 | 2 years ago |
| SMA: Bullish | Jun 14, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 13, 2024 | 2 years ago |
| MACD: Sell Signal | May 20, 2024 | 2 years ago |
| SMA: Bearish | May 16, 2024 | 2 years ago |
| SMA: Bullish | May 13, 2024 | 2 years ago |
| MACD: Buy Signal | May 13, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 26, 2024 | 2 years ago |
Newest 20 of 76.
Key statistics
- Market cap
- 3.25M
- Enterprise value
- 16.78M
- Trailing P/E
- 1.21
- Forward P/E
- -4.17
- PEG ratio
- 0.00
- Price / sales
- 0.56
- Price / book
- 0.00
- EPS (TTM)
- 0.69
- Beta
- 1.44
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -122.80%
- Revenue (TTM)
- 5.77M
- Revenue growth
- 481.40%
- Free cash flow
- 1.44M
- Total cash
- 942.93K
- Total debt
- 5.38M
- Return on equity
- 0.00%
- Shares outstanding
- 3.91M
- Short % of float
- 0.05%
- 50-day average
- 0.773565
- 200-day average
- 0.901579
Analyst view
Consensus: hold
Hold
Price target (mean) 0.00
Next earnings
Nov 11, 2024
Expected Nov 11, 2024. Consensus EPS estimate 0.00.
Financials — quick view
INVO Revenue — quarterly 1.84M
INVO Net income — quarterly -2.25M
INVO EPS — quarterly -0.62
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
About INVO Bioscience, Inc.
INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- invobioscience.com
News
- INVO Fertility Announces a 1:4 Reverse Stock Split Effective Pre-Market Opening on October 30, 2026
- INVO Fertility to Participate in the Lytham Partners Fall 2026 Investor Conference
- INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
- INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International
- INVO Fertility Stock Surges Following Q2 Earnings Beat
- INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability
- Why INVO Fertility Stock Is Surging Friday Afternoon
- INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure
- INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Quarterly Report on Form 10-Q
- INVO Fertility Announces Fiscal Year 2025 Financial Results
Your note
Sign in to keep a note on INVO — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 1.38% | 54,058 | 45.03K | Jun 29, 2024 |
| Geode Capital Management, LLC | 0.83% | 32,614 | 27.17K | Jun 29, 2024 |
| Two Sigma Securities, LLC | 0.41% | 15,968 | 13.30K | Jun 29, 2024 |
| Virtu Financial LLC | 0.32% | 12,409 | 10.34K | Jun 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.13% | 5,106 | 4.25K | Jun 29, 2024 |
| Osaic Holdings Inc | 0.01% | 250 | 208 | Jun 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.38% | 54,058 | 45.03K | Jun 29, 2024 |
| Fidelity Extended Market Index Fund | 0.50% | 19,530 | 16.27K | Aug 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.16% | 6,166 | 5.14K | Aug 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.13% | 5,055 | 4.21K | Aug 30, 2024 |
| Fidelity Total Market Index Fund | 0.03% | 1,199 | 998 | Aug 30, 2024 |